Patent- System and method for improved determination of a brain response state in Australia has now been granted and SensoDetect have achieved the registrings- and approvalpapers via the patent attorney AWA patent. The patent is valid until 2037. For further reading go to AktieTorget.
SensoDetect is discussing a collaboration with one of Bolivia’s major distributors. The distributor has contacted SensoDetect regarding cooperation during last year and a first meeting and presentation took place at the beginning of the year in Bolivia. After dialogue during the spring and summer the distributor will now visit Sweden for further talks. For
The new board and the team of SensoDetect have the last 4 months worked in a focused manner to detail the long-term strategy of the company as well as securing the funds and resources to realize the same. Thanks to this work and the strong evidence presented in the research from Uppsala University Hospital, ”Auditory
EuroAsia patents 2108550EA has been granted. The SensoDetects main portfolio is approved in the Euroasia (Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan) area. IP portfolio strenghtens through this in especially one very important market, Russia. In these countries, there is similar problems in Psychiatry as in the rest of the world.
The technology from SensoDetect has been proven through research. A recent blind study at Uppsala University Hospital published in 2017, using SensoDetect technology concluded “The ABR profiling tests discriminated schizophrenia and ADHD versus healthy controls with high sensitivity and specificity”. For further reading, go to AktieTorget.
Vivantes hospital in Berlin will use Sensodetect Technology to measure impact of dialyses on patiens with kidney disease. One of the main challenges for patients with kidney disease is the impact dialysis has on the brain (structural brain abnormalities and cognitive impairment). This can lead to the patient not attending treatments or mismanaging their
After finishing the open study of brainstem abnormalities detected in children and adolescents with autism (autism spectrum disorders), is now the research team on BUP in Eslöv ahead with a blind study to ensure they found abnormalities related to autism. 150 patients seeking to BUP in Eslöv regardless of the reason, will participate in the